India’s market for anti-obesity medicines has expanded almost fivefold in four years, rising from about INR 133 crore in 2021 to more than INR 628 crore by mid-2025, according to industry data cited by health-policy researchers. The surge is being driven largely by demand for glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for diabetes care but now widely prescribed for weight loss. Semaglutide accounts for the bulk of the business, generating roughly INR 397 crore in sales—69 percent of it from the oral brand Rybelsus—while the injectable version marketed as Wegovy continues to gain ground. Tirzepatide, launched under the Mounjaro label this year, booked about INR 26 crore in June 2025 alone. Analysts project the overall Indian market could climb to about INR 4,564 crore by FY 2033, implying a compound annual growth rate of 23.5 percent. Rapid uptake has exposed regulatory and equity gaps. High prices are pushing some consumers toward black-market or compounded versions, while uneven medical oversight raises the risk of misuse and psychological dependence. Health experts are urging the Central Drugs Standard Control Organisation to tighten surveillance, curb illicit online sales and broaden safe access, warning that without stronger oversight the benefits of the new therapies could deepen, rather than narrow, India’s health-care divides.